AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Xenon Pharmaceuticals Announces Equity Inducement Grants for New Employees Under Nasdaq Listing Rule 5635(c)(4)
ByAinvest
Friday, Aug 29, 2025 4:03 pm ET1min read
Xenon Pharmaceuticals has granted 55,300 share options to seven new employees as part of Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $38.60 per share, vest over four years, and are subject to the terms of the company's 2025 Inducement Equity Incentive Plan. Xenon is a neuroscience-focused biopharmaceutical company with a lead molecule, azetukalner, in Phase 3 clinical trials for epilepsy, major depressive disorder, and bipolar depression.
VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced the granting of 55,300 share options to seven new non-officer employees. The options were approved by the Compensation Committee of the Company’s Board of Directors and are subject to the terms of the company's 2025 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4) [1].The share options have an exercise price of $38.60 per common share, which matches the closing price per share on the grant date of August 28, 2025. The options vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and the remaining 75% vesting monthly over the next three years. Each option has a 10-year term [2].
Xenon Pharmaceuticals is dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. The company's lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of promising potassium and sodium channel modulators in Phase 1 development for the potential treatment of pain [3].
References:
[1] https://www.globenewswire.com/news-release/2025/08/29/3141770/33485/en/Xenon-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
[2] https://www.stocktitan.net/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-j5vw4g7vc0ax.html
[3] https://www.marketscreener.com/news/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ce7c50dddc8af424
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet